UB Paderborn / Katalog / Suche / in CDI

Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

Allergy (Copenhagen), 2020-01, Vol.75 (1), p.116-126

2020

Volltextzugriff (PDF)

Dupilumab has a profound effect on specific‐IgE levels of several food allergens in atopic dermatitis patients

Allergy (Copenhagen), 2023-03, Vol.78 (3), p.875-878

2023

Volltextzugriff (PDF)

The long‐term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry

Contact dermatitis, 2022-08, Vol.87 (2), p.185-191

2022

Volltextzugriff (PDF)

A meta‐analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis

British journal of clinical pharmacology, 2023-01, Vol.89 (1), p.61-79

2023

Volltextzugriff (PDF)

Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients

Clinical and experimental allergy, 2022-06, Vol.52 (6), p.801-805

2022

Volltextzugriff (PDF)

Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study

Journal of dermatology, 2019-08, Vol.46 (8), p.680-685

2019

Volltextzugriff (PDF)

Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Allergy (Copenhagen), 2022-11, Vol.77 (11), p.3398-3407

2022

Volltextzugriff (PDF)

Differential dynamics of TARC during JAK‐inhibitor therapy compared to biological therapies targeting type 2 inflammation

Clinical and experimental allergy, 2024-04, Vol.54 (4), p.294-296

2024

Volltextzugriff (PDF)

EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Allergy (Copenhagen), 2020-12, Vol.75 (12), p.3287-3289

2020

Volltextzugriff (PDF)

Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies

Clinical and experimental allergy, 2023-05, Vol.53 (5), p.582-585

2023

Volltextzugriff (PDF)

Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry

Allergy (Copenhagen), 2020-09, Vol.75 (9), p.2376-2379

2020

Volltextzugriff (PDF)

Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry

Pediatric allergy and immunology, 2024-06, Vol.35 (6), p.e14178-n/a

2024

Volltextzugriff (PDF)

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry

Pediatric allergy and immunology, 2022-12, Vol.33 (12), p.e13887-n/a

2022

Volltextzugriff (PDF)

Conjunctival inflammation in dupilumab‐treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study

Allergy (Copenhagen), 2021-12, Vol.76 (12), p.3814-3817

2021

Volltextzugriff (PDF)

Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment

Clinical and experimental allergy, 2019-12, Vol.49 (12), p.1641-1644

2019

Volltextzugriff (PDF)

Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity

Allergy (Copenhagen), 2019-11, Vol.74 (11), p.2240-2243

2019

Volltextzugriff (PDF)

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs

Clinical and translational allergy, 2023-03, Vol.13 (3), p.e12236-n/a

2023

Volltextzugriff (PDF)

Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials

British journal of dermatology (1951), 2022-12, Vol.187 (6), p.888-899

2022

Volltextzugriff (PDF)

EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with cyclosporin A

Allergy (Copenhagen), 2019-03, Vol.74 (3), p.613-617

2019

Volltextzugriff (PDF)

Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis

Journal of allergy and clinical immunology, 2017-03, Vol.139 (3), p.1065-1065

2017

Volltextzugriff (PDF)

Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series

Clinical and experimental allergy, 2023-05, Vol.53 (5), p.586-589

2023

Volltextzugriff (PDF)

Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis

Journal of allergy and clinical immunology, 2017-09, Vol.140 (3), p.730-737

2017

Volltextzugriff (PDF)

Dupilumab‐associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis

Allergy (Copenhagen), 2023-08, Vol.78 (8), p.2266-2276

2023

Volltextzugriff (PDF)

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

The New England journal of medicine, 2023-10, Vol.389 (17), p.1579-1589

2023

Volltextzugriff (PDF)

Management of dupilumab‐associated conjunctivitis in atopic dermatitis

Journal der Deutschen Dermatologischen Gesellschaft, 2019-05, Vol.17 (5), p.488-491

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

Dupilumab has a profound effect on specific‐IgE levels of several food allergens in atopic dermatitis patients

The long‐term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry

A meta‐analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis

Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients

Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study

Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Differential dynamics of TARC during JAK‐inhibitor therapy compared to biological therapies targeting type 2 inflammation

EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies

Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry

Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry

Conjunctival inflammation in dupilumab‐treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study

Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment

Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs

Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials

EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with cyclosporin A

Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis

Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series

Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis

Dupilumab‐associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

Management of dupilumab‐associated conjunctivitis in atopic dermatitis

Suchergebnisse filtern